A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.
Humans
Pemetrexed
/ pharmacology
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Lung Neoplasms
/ drug therapy
Carcinoma, Transitional Cell
/ drug therapy
Urinary Bladder Neoplasms
/ drug therapy
Antineoplastic Agents
/ therapeutic use
Protein Kinase Inhibitors
/ adverse effects
Adenocarcinoma
/ drug therapy
Disease Progression
Bosutinib
adenocarcinoma
chemotherapy
chronic myelocytic leukemia
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
03 12 2022
03 12 2022
Historique:
received:
26
10
2022
revised:
28
11
2022
accepted:
02
12
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Src is overexpressed in various cancers, including 27% of non-small cell lung cancer NSCLC, and is correlated with poor clinical outcomes. We hypothesize that Src kinase inhibitors, including Bosutinib, may exhibit clinical synergy in combination with the antifolate drug pemetrexed. In this Phase I, dose-escalation, safety, and maximum tolerated dose (MTD)-determining study, 14 patients with advanced metastatic solid tumors that had progressed on "standard of care" chemotherapy were enrolled in a 3 + 3 dose escalation study. Oral Bosutinib was administered once daily beginning on day 1, where the first cohort started at an oral dose of 200 mg daily with pemetrexed 500 mg/m
Identifiants
pubmed: 36547158
pii: curroncol29120744
doi: 10.3390/curroncol29120744
pmc: PMC9776616
doi:
Substances chimiques
Pemetrexed
04Q9AIZ7NO
bosutinib
5018V4AEZ0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9461-9473Références
Oncogene. 2000 Nov 20;19(49):5636-42
pubmed: 11114744
Annu Rev Cell Dev Biol. 1997;13:513-609
pubmed: 9442882
Ann Oncol. 2008 Jul;19(7):1219-1223
pubmed: 18388349
Biochim Biophys Acta. 1996 Jun 7;1287(2-3):121-49
pubmed: 8672527
Cancer Metastasis Rev. 2003 Dec;22(4):337-58
pubmed: 12884910
Cell. 1987 Apr 10;49(1):65-73
pubmed: 3103925
Clin Cancer Res. 2011 Apr 1;17(7):1713-21
pubmed: 21300758
J Exp Med. 1911 Apr 1;13(4):397-411
pubmed: 19867421
J Thorac Oncol. 2011 Jan;6(1):64-70
pubmed: 21119545
Int J Cancer. 2012 Apr 15;130(8):1777-86
pubmed: 21618517
J Thorac Dis. 2010 Dec;2(4):199-204
pubmed: 22263047
Growth Factors. 2005 Sep;23(3):233-44
pubmed: 16243715
Gynecol Oncol. 2003 Jan;88(1):73-9
pubmed: 12504632
Mol Oncol. 2016 May;10(5):719-34
pubmed: 26827254
Ann Oncol. 2021 Feb;32(2):269-278
pubmed: 33130216
Nat Commun. 2017 Apr 24;8:15059
pubmed: 28436416
J Clin Oncol. 2013 Aug 10;31(23):2895-902
pubmed: 23835707
Front Biosci (Landmark Ed). 2012 Jun 01;17(6):2059-69
pubmed: 22652764
Cancers (Basel). 2021 Jul 08;13(14):
pubmed: 34298648
J Clin Oncol. 2012 Oct 1;30(28):3486-92
pubmed: 22949154
Int J Hematol. 2015 Feb;101(2):154-64
pubmed: 25540064
Mol Cancer Ther. 2010 May;9(5):1128-35
pubmed: 20406945
Clin Cancer Res. 2012 Jul 1;18(13):3580-91
pubmed: 22586301
Eur J Cancer. 1992;28(2-3):372-7
pubmed: 1375484
J Hematol Oncol. 2017 Nov 13;10(1):172
pubmed: 29132432
J Clin Oncol. 2010 Oct 20;28(30):4609-15
pubmed: 20855820
Mol Cancer Ther. 2016 Jul;15(7):1535-44
pubmed: 27196762
Exp Cell Res. 2014 Oct 15;328(1):20-31
pubmed: 25128812
Proc Natl Acad Sci U S A. 1979 Apr;76(4):1804-8
pubmed: 221907
Acta Biochim Biophys Sin (Shanghai). 2010 Jul;42(7):496-501
pubmed: 20705589
Clin Cancer Res. 2012 Nov 1;18(21):5911-23
pubmed: 22896656
Recent Results Cancer Res. 2014;201:81-97
pubmed: 24756786
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Oncogene. 2004 Oct 18;23(48):7906-9
pubmed: 15489908
Clin Cancer Res. 2012 Feb 15;18(4):1092-100
pubmed: 22179664
Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899
pubmed: 31166114
Oncologist. 2009 Mar;14(3):253-63
pubmed: 19221167
Ann Oncol. 2012 Mar;23(3):610-617
pubmed: 21700731
Br J Cancer. 2014 Nov 25;111(11):2058-66
pubmed: 25290090
Oncotarget. 2014 Sep 15;5(17):7328-41
pubmed: 25193862